XML 52 R36.htm IDEA: XBRL DOCUMENT
v3.22.4

Earnings per Share (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Earnings Per Share [Abstract] |
Schedule of Earnings Per Share, Basic and Diluted | The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):
| Years Ended December 31,
| 2022 |  | 2021 |
Numerator |  |  |  |
Consolidated net income | $ | 230,064 |  |  | $ | 1,241,201 |  |
Less: Net income attributable to Continuing Investors Partnerships | 23,775 |  |  | 297,321 |  |
Less: Net income attributable to Legacy Investors Partnerships and RPSFT | 163,457 |  |  | 324,152 |  |
Net income attributable to Royalty Pharma plc - basic and diluted | $ | 42,832 |  |  | $ | 619,728 |  |
Denominator |  |  |  |
Weighted average Class A ordinary shares outstanding - basic | 437,963 |  |  | 414,794 |  |
Add: Dilutive effect of unvested RSUs | 9 |  |  | 8 |  |
Weighted average Class A ordinary shares outstanding - diluted | 437,972 |  |  | 414,802 |  |
Earnings per Class A ordinary share - basic | $ | 0.10 |  |  | $ | 1.49 |  |
Earnings per Class A ordinary share - diluted | $ | 0.10 |  |  | $ | 1.49 |  |
|  | Year Ended December 31,
|  | 2020
Numerator |  |
Consolidated net income |  | $ | 1,701,954 |
Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1) |  | 479,842 |
Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO |  | 316,993 |
Less: Net income attributable to Legacy Investors Partnerships and RPSFT |  | 409,921 |
Net income attributable to Royalty Pharma plc - basic and diluted |  | $ | 495,198 |
Denominator |  |
Weighted average Class A ordinary shares outstanding - basic |  | 375,444 |
Add: Dilutive effect of unvested RSUs |  | 11 |
Weighted average Class A ordinary shares outstanding - diluted |  | 375,455 |
Earnings per Class A ordinary share - basic |  | $ | 1.32 |
Earnings per Class A ordinary share - diluted |  | $ | 1.32 |
(1)Reflected as Net income attributable to Royalty Pharma plc on the consolidated statements of operations.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration